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Summary
Introduction: Levetiracetam (LEV) is approved for use as add-on therapy in adult
patients with partial epilepsy. It is apparent from clinical trials that up to 8% of
previously drug-resistant patients may be rendered seizure-free by adding-on
levetiracteam. As yet there is no way of predicting these unexpectedly responsive
patients. We set out to identify our previously refractory patients who had
demonstrated unexpected responsiveness to add-on therapy with levetiracetam,
and compared these to patients who had not responded to the drug. We then
attempted to characterise any clinical features that differentiated these groups of
patients.
Methods: We included all patients with a history of present or previous exposure to
levetiracetam who had been unresponsive to at least two other prior anti-epileptic
drugs (AEDs) and recorded their demographic and clinical data. We divided response
into (a) ‘seizure-free’ (seizure-free for a minimum of 6 months after commencing
LEV); (b) ‘partial >50%’ (greater than 50% reduction in seizures for a minimum of 6
months after commencing LEV); (c) ‘honeymoon’ (seizure-free for less than 6
months after commencing LEV and then returned towards baseline frequency);
and (d) ‘no-response’. For the purpose of analysis we considered the ‘seizure-free’
and ‘partial >50%’ groups as ‘responders’, and the ‘no response’ group as ‘non
responders’.
Results: 344 patients were included in the analysis. Fifty-six patients (16.3%) were
rendered seizure-free on levetiracetam. Idiopathic generalised epilepsy and post-
traumatic partial epilepsy were more common in the responder than the non-
responder group ( p = 0.005 and 0.05 respectively). Lamotrigine was used signifi-
cantly more often in combination with levetiracetam in responders than non-
responders ( p = 0.003). The mean daily dose of levetiracetam was lower in respon-
ders than non-responders.* Corresponding author. Tel.: +353 1 8092055; fax: +353 1 8092090.
E-mail address: normandelanty@eircom.net (N. Delanty).
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Discussion: A higher than expected number of previously drug-resistant patients
was rendered seizure-free by add-on therapy with levetiracetam. Those who
respond best appear to do so at relatively low doses and our data suggest the
possibility of a beneficial pharmacodynamic interaction between levetiracetam and
lamotrigine. We were unable to identify any clinical factors that clearly predicted
which patients would become seizure-free and we hypothesise that response may be
determined by genetic or molecular factors. All drug-resistant patients, including
those being assessed for surgery, should be considered for a trial of levetiracetam,
regardless of their epilepsy classification.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Levetiracetam, the S-enantiomer of alpha-ethyl-2-
oxo-1-pyrrolidine acetamide, is approved for use as
add-on therapy in adult patients with partial epi-
lepsy.1 The effectiveness of the drug in this regard
was established in three pivotal multi-centre, ran-
domized, double blind placebo-controlled trials,
comprising a total of 904 patients.2—4 At the
3000 mg dose, a maximum of 8% of patients became
seizure-free in these trials. The drug is currently
undergoing trials as monotherapy for new-onset
partial epilepsy and for the treatment of idiopathic
generalised epilepsy (IGE) where preliminary data
suggest it has efficacy.5—7 The drug appears to have a
unique mechanism of action, binding to the synaptic
vesicle protein SV2A. Although the exact effect of
this is unclear, it is believed to involve modulation of
the synaptic release of neurotransmitters.8 The drug
has a favourable pharmacokinetic profile with rapid
oral absorption, bioavailability of nearly 100%, lin-
ear pharmacokinetics at oral dosing of 500—5000 mg
and less than 10% protein binding. It is excreted two-
thirds unchanged by the kidney.9
It is apparent both from the initial clinical trials of
the drug and from post-release clinical experience
that some, previously drug-resistant patients, are
exquisitely sensitive to add-on therapy with levetir-
acetam and may be rendered seizure-free.2—4,10
Indeed, in a small pilot study of 11 patients on
the waiting list for epilepsy surgery at our institu-
tion, the addition of levetiracetam resulted in four
patients being removed from the waiting list due to
dramatic improvement in seizure control.11 There is
currently no way of predicting these potentially
responsive patients. The ability to do this would
be of particular clinical benefit as early recognition
of these patients might prevent unnecessary trials
of other anti-epileptic drugs and potential drug
toxicity. It might also obviate the need for epilepsy
surgery in some patients.
In this study, we therefore set out to identify
previously drug-resistant patients who had demon-
strated unexpected responsiveness to add-on ther-apywith levetiracetam, resulting in seizure freedom,
and compared these to patients who had not respo-
nded to the drug. We then attempted to identify any
predictors of response by characterising the clinical
features that differentiated these groups of patients.Methods
Patients were selected from the epilepsy clinic at
our institution. We included all patients with a
history of present or previous treatment with leve-
tiracetam who had failed at least two other prior
anti-epileptic drugs (AEDs), appropriate for their
epilepsy classification, due to non-responsiveness.
We defined non-responsiveness as a failure to sub-
stantially improve seizure-control despite treat-
ment with the maximum tolerated dose of that
drug, necessitating the addition or substitution of
another AED. Data were collected using a combina-
tion of patient interview and review of patient
records. We recorded demographic data including
age and sex of patient; epilepsy diagnosis including
cause if known; duration of exposure and maximum
dose of levetiracetam; combination of AEDs while on
levetiracetam and all other AEDs; average seizure
frequency in the 6-months prior to commencing
levetiracetam; response to treatment and any side
effects experienced. We divided response into (a)
‘seizure-free’, if patients were rendered seizure
free for a minimum of 6 months after commencing
therapy; (b) ‘partial>50%’, if patients had a greater
than 50% reduction in seizures for a minimum of 6
months after commencing therapy; (c) ‘honey-
moon’, if patients had been rendered seizure free
for less than 6 months after commencing therapy
and then returned towards baseline frequency; and
(d) ‘no-response’, if patients had (i) a less than 50%
reduction in their seizures; (ii) no improvement; or
(iii) a worsening of their seizure control, despite
taking the maximum tolerated dose. Seizure rates
were estimated using a combination of patient
report and review of seizure diaries. For the purpose
of analysis we considered the ‘dramatic’ and
Pre
d
ictin
g
d
ru
g-re
sista
n
t
p
atie
n
ts
w
h
o
re
sp
o
n
d
to
ad
d
-o
n
th
e
rap
y
w
ith
le
ve
tirace
tam
389
Table 1 Summary of patient data
Response n M/F Diagnoses Average no.
of current
drugs (inc. LEV)
Average seizures
prior to LEV
(per month)
Drug used
most frequently
in combination
Average no.
of previous
drugs
Average
daily
dose (g)
Average
exposure
time (months)
% with
adverse
effects (%)
Seizure-free 56 26/30 12 IGE (21%) 2.3 6.8 LTG (24/56) 2.6 2.2 29.3 4
4 SGEK (7%) VAL (15/56)
2 SGEU (3%) CBZ (11/56)
16 SLREK (28%)
20 SLREU (36%)
2 Unclassified (3%)
Partial >50% 46 22/24 4 IGE (9%) 2.6 7.1 LTG (21/46) 2.3 2.65 29.2 16
0 SGEK (0%) VAL (10/46)
3 SGEU (7%) PHY (8/46)
23 SLREK (50%)
13 SLREU (28%)
3 Unclassified (7%)
Honey-moon 18 10/8 2 IGE (11%) 2.8 5.7 LTG (8/18) 2.4 2.7 27.3 19
0 SGEK (0%) VAL (5/18)
2 SGEU (11%) PHY (5/18)
8 SLREK (44%)
6 SLREU (33%)
0 Unclassified (0%)
No-response 224 102/122 16 IGE (8%) 2.7 7.4 VAL (54/224) 4.0 2.95 34.6 18
6 SGEK (3%) LTG (49/224)
16 SGEU (7%) PHY (40/224)
86 SLREK (38%)
92 SLREU (41%)
8 Unclassified (4%)
IGE, idiopathic generalised epilepsy; SGEK, symptomatic generalised epilepsy cause known; SGEU, symptomatic generalised epilepsy cause unknown; SLREK, symptomatic localisation
related cause known; symptomatic localisation related cause unknown. (LTG, lamotrigine; VAL, valproate; PHY, phenytoin)
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Table 2 Summary of known etiologies in responders and non-responders
Hippocampal sclerosis Cortical dysplasia Tumour Trauma Other
Responders 10 (10%) 5 (5%) 7 (7%) 7 (7%) 9 (9%)
Non-responders 29 (13%) 9 (3%) 12 (5%) 6 (2%) 31 (14%)
Honeymoon 4 (22%) 0 (0%) 1 (5%) 1 (5%) 3 (16%)
Figures are shown as the absolute number and as a percentage of the total number of responders and non-responders. Note the similar
percentages in each group. (‘Other’ includes CNS infection, strokes, haemorrhage, vascular malformations and congenital
anomalies.)‘partial >50%’ groups as ‘responders’, and the ‘no
response’ group as ‘non responders’.Results
In total 364 drug resistant patients were identified
who had been exposed to levetiracetam. Twenty
patients were excluded because they had either
stopped the drug due to intolerable side effects
(n = 14) (psychosis in three, mood changes in six,
severe fatigue in three and dizziness in two) and
hence response could not be judged, or had not been
on the drug for a sufficient period to make a reliable
assessment of response (n = 6). A summary of
patient data for the remaining 344 patients is shown
in Table 1.
Fifty-six patients (16.3%) were rendered seizure-
free for a minimum of 6 months following the addi-
tion of levetiracetam therapy. If we include only
those with localization-related epilepsy, the sei-
zure-free percentage is 13.6% (36/264). The mean
duration of seizure freedom was 29.2 months (range
7—59 months). Fifty-one of the fifty-six patients had
follow-up data for at least 1 year. As can be noted
from Table 1, the group consisted of essentially
equal numbers of males and females and featured
a range of epilepsy types, most commonly localisa-
tion-related epilepsy of unknown cause (36%), fol-
lowed by localisation-related epilepsy of known
cause (28%), idiopathic generalised epilepsy (21%)
and symptomatic generalised epilepsy (10%). The
mean number of drugs that patients had been
exposed to prior to commencing levetiracetam
(including previous and concurrent drugs) was four
(range 2—7). All patients were on a polytherapy
regimen that included levetiracetam and at least
one other drug (mean 2.3 drugs, range 2—4, includ-
ing levetiracetam). The commonest drug used in
combination with levetiracetam in these patients
was lamotrigine, in 43%. Themean daily dose used in
these patients was 2.2 g (range 500 mg to 3 g).
The ‘partial responder’, ‘honeymoon’ and ‘no-
response’ groups were broadly similar to the sei-
zure-free group in terms of patient demographics,
epilepsy diagnoses and drug history. Males andfemales were present to a similar degree in each
group. The various epilepsy syndromes were repre-
sented in each group to a similar extent, except for
IGE, which was significantly less common in the no-
response group than in the seizure-free group
(x2 = 7.73, p = 0.005). Apart from one individual in
the ‘no-response’ group, all patients in these three
groups had taken levetiracetam as part of a poly-
therapy regimen. For patients with a partial
response of >50% reduction in seizures, the drug
used most commonly in combination with levetir-
acetam was again lamotrigine (46%). By contrast, in
patients that had no response to levetiracetam,
lamotrigine was used concomitantly in only 22%.
When compared to the seizure-free and >50%
responder groups, this difference was statistically
significant (x2 = 8.82, p = 0.0029). The most fre-
quently used concomitant drug in the no-response
group was valproate (24%). The average daily dose
of levetiracetam was higher in these groups com-
pared to the seizure-free group, averaging almost
3 g per day in the no-response group.
Among the patients with partial epilepsy due to a
known cause, the distribution of aetiologies was
similar between responders and non-responders
(see Table 2), although patients with post-traumatic
epilepsy were more commonly represented in the
responder group (x2 = 3.87, p = 0.05). However, the
number of patients with post-traumatic epilepsy
was small in each group. Hippocampal sclerosis
was the commonest known aetiology in both respon-
ders and non-responders.Discussion
In this study 16% of previously drug-resistant patients
were rendered seizure-free for at least 6monthswith
the addition of levetiracetam, and 15% were seizure-
free for at least 1 year. 13.5% of patients with drug-
resistant partial epilepsy were rendered seizure-
free. This figure is higher than the maximum 8%
observed in initial clinical trials using levetiracetam
as add-on therapy in partial epilepsy,2—4 and 8.8%
observed in a post-licensing surveillance study.10 It
also considerably higher than the remission rates
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(7%) and three drugs (3%).12 Our figures are not based
on prospective, placebo-controlled trials but are
relevant nonetheless. Patient selection was based
solely on a history of failure to respond to at least
two appropriate anti-epileptic drugs prior to the
addition of levetiracetam. Patients typically attend
our clinic every 3—6 months and we are therefore
confident that good follow-updatawas achievedover
the study period.
The principle aim of the study was to determine if
these responsive patients were somehow predict-
able. We were unable to identify any clinical factors
that clearly predicted whether drug-resistant
patients would become seizure-free with the addi-
tion of levetiracetam. A diagnosis of drug-resistant
IGE and post-traumatic partial epilepsy were statis-
tically associated with a better response but,
although interesting, the overall numbers are too
small to draw any firm conclusions. Of note hippo-
campal sclerosis was present to a similar extent in
both responders and non-responders. In fact, based
on this data, patients with hippocampal sclerosis
who had failed at least two prior AEDs, had a better
than one in three chance of having at least a 50%
reduction in seizures on levetiracetam.
In terms of drug-exposure, the combination of
levetiracetam and lamotrigine was used signifi-
cantly more often in responders than in non-respon-
ders. This raises the possibility of a beneficial
pharmacodynamic interaction between the two,
although there is currently no experimental evi-
dence to support this. Alternatively, it may simply
represent a prescribing bias in our department. Also
of note, the mean daily dose of levetiracetam was
lowest in the seizure-free group suggesting that
patients who respond best do so at relatively low
doses and that increasing to the maximum dose in
patients who have shown no response at lower doses
may not be worthwhile.
If clinical features do not reliably predict patients
who are likely to respond to add-on therapy with
levetiracetam, what other factors are likely to play a
role? Levetiracetam is a compound with a unique
mechanism of action among antiepileptic drugs. It
binds to an integral membrane protein, SV2A, pre-
sent on synaptic vesicles and also present in endo-
crine cells.13 It has been demonstrated that
compounds with increasing affinity for this protein
have increasing anti-seizure properties in animal
models of epilepsy, suggesting that the drug exerts
its anti-seizure effect through this mechanism.8 The
protein is believed to interact with the presynaptic
protein synaptotagmin, and affect calcium-depen-
dent fusion of synaptic vesicles to the plasma mem-
brane and release of neurotransmitters.14,15 Itsprecise action is unknown but one theory is that
binding of levetiracetam may enhance a function
of SV2A that inhibits abnormal bursting in epileptic
circuits.8 Even more interesting is that the drug
appears to have no effect on either the electrophy-
siology or standard amino acid neurotransmitter
release of normal neuronal tissue.16—18 This suggests
that the drug may modulate a function of SV2A
present only under pathophysiological conditions,
as might be found in epileptic brain tissue. It is
possible therefore that those patients who respond
best to levetiracetamhave an alteration in either the
expression or function of SV2A, for example up-reg-
ulation of the protein. Alternatively, patients who
respond to levetiracetammay have genetic variation
in SV2A or related proteins that results in a higher
affinity for the drug, a hypothesis we are currently
examining in pharmacogenetic studies. Until such
data becomes available, it seems reasonable to sug-
gest that all drug-resistant patients, including those
being assessed for surgery, should be considered for a
trial of add-on therapy with levetiracetam, regard-
less of their epilepsy classification.References
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